The Chemical Data Science by Scientific and Technological Knowledge in Big Data of the antiretrovirals patents

The magnitude of information science in the 21st century is undoubtedly true in all areas of science. The chemical science and technology sector advanced much more in the first decade than in the previous 50 years. The more than 100 million patents registered in the European Patent Office (EPO) provide an unprecedented source of scientific and technological information in the history of mankind. The technological management of this information is exploited to develop technological advances in scientific, technological and educational organizations and companies. New standards of product and process safety and effectiveness have been introduced across the world and public and private business strategies are under constant review to comply with the prevailing paradigm. The health sector releases more than 1 million papers a year on scientific progress, while technological (patents) advances 10%a.a. Thus, a case study in new chemical entities in antiretroviral will provide a contribution to reflection for the business in research, development and innovation in health. In 2017, 03 lists of strategic products for the Brazilian Health System were changed. Using new intelligence systems in intellectual property, the government has adopted new strategic partnerships with the private sector and were conceived in 2017 with budgets of more than US$ 2 billion. The 2017 list contemplates 56 strategic medicines, with 28 drugs to fight HIV - further 88 that are under development. Using SciFinder Scholar® and EPO database 4.554 HIV patents were extracted and processed in software vantage: 20 ARV used in BraziL: 06 are NRTI, 03 are NNRTI, 07 are PI, 02 are INI and 02 are FI. Dolutegravir more important key molecule 3,4,5-Piperidinetriol, 1-[(3-phenyl-2-propen-1-yl)oxy]- (C14 H19 N O4); second Raltegravir. Temporal evolution of the patent applications per priority year is shown beside. Knowledge management, using IT tools, could become a great ally in helping decision-makers in the private and public sectors alike. Technologies that are not protected in each country or which expire may then be produced generically and incremental innovations may be made, etc. Chemical patents documents can serve as a source of information. It was possible to identify common indicators in an analysis of patenting per class indicating emergence of new classes of drugs for HIV/Aids treatment. Major technological developments are EUA and China.